ConexiantFDA Approves HRT Label Changes

The FDA removed cardiovascular disease, breast cancer, and probable dementia risk statements from boxed warnings on six menopausal hormone therapy products, citing updated scientific evidence. With 41 million US women aged 45–64 and only 2 million receiving HRT prescriptions, the label change directly challenges decades of clinical underprescribing.

⚖️ Professional Impact

• Boxed warning language that drove widespread HRT avoidance after the 2002 WHI study no longer reflects FDA’s current evidence standard
• FDA review confirms women initiating HRT within 10 years of menopause or before age 60 see reductions in all-cause mortality and fractures
• 29 manufacturers received revision requests; six products approved across systemic combination, estrogen-alone, progestogen-alone, and topical vaginal estrogen categories
• Label changes create new informed consent obligations so patients previously counseled against HRT based on old warnings may need updated conversations

🎯 Action Items

• Reassess HRT candidacy for patients previously declined based on old boxed warning language
• Update patient counseling materials to reflect revised FDA safety language
• Document individualized risk-benefit discussions referencing the updated label language
• Review prescribing patterns against the 10-year/age-60 initiation window now supported by FDA

More in HRT